PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by David A. Khan and Enrico CompalatiManagement of rhinosinusitis: an evidence based approachPara, Andrew J.a; Clayton, Elisabethb; Peters, Anju T.bAuthor Information aDepartment of Medicine bDivision of Allergy/Immunology, Department of Medicine, Northwestern University, Chicago, Illinois, USA Correspondence to Anju T. Peters, MD, 211 E. Ontario, #1000, Chicago, IL 60611, USA. Tel: +312 695 4000; fax: +312 695 4141; e-mail: [email protected] Current Opinion in Allergy and Clinical Immunology: August 2016 - Volume 16 - Issue 4 - p 383-389 doi: 10.1097/ACI.0000000000000276 Buy Metrics Abstract Purpose of review The most recent recommendations for the management of both acute (ARS) and chronic rhinosinusitis (CRS) based on the strongest data available for each treatment modality are summarized in this review. The clinical relationships between CRS and its comorbidities are also discussed. Recent findings The most promising advances in rhinosinusitis management involve the use of mAbs (anti-IgE, anti-IL-5, anti-IL-4Rα) in trials of CRS with nasal polyposis. Otherwise, the mainstays of treatment for both ARS and CRS have largely remained the same over the past several years. Summary The treatment of ARS primarily involves symptomatic control with intranasal corticosteroids and nasal saline irrigation; antibiotics should be reserved for the patients who are believed to have bacterial rhinosinusitis. Treating CRS effectively involves using intranasal corticosteroids and irrigation, systemic corticosteroids, and potentially systemic antibiotics. Biologics (mAbs) have shown benefit in clinical studies. Providers should also be aware of concomitant disease processes that may afflict patients with CRS. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.